gefapixant U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review KENILWORTH, N.J.–(BUSINESS WIRE) March 1, 2021 — Merck (NYSE: MRK), known as MSD outside
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
